Previously treated moderately to severely active Crohn's disease (NICE TA888)
1.1 Risankizumab is recommended as an option for treating moderately to severely active Crohn's disease in people 16 years and over, only if:
- the disease has not responded well enough or lost response to a previous biological treatment, or
- a previous biological treatment was not tolerated, or
- tumour necrosis factor (TNF)-alpha inhibitors are not suitable.
Risankizumab is only recommended if the company provides it according to the commercial arrangement.